Tobias Hartmann

List of Publications by Year
in descending order

Version: 2024-02-01

118 papers	8,765 citations	38660 50 h-index	43802 91 g-index
123 all docs	123 docs citations	123 times ranked	10548 citing authors

#	Article	IF	Citations
1	Distinct sites of intracellular production for Alzheimer's disease AÎ²40/42 amyloid peptides. Nature Medicine, 1997, 3, 1016-1020.	15.2	716
2	Analysis of Heterogeneous Î²A4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay. Journal of Biological Chemistry, 1996, 271, 22908-22914.	1.6	461
3	Aggregation promoting C-terminal truncation of Â-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2162-2167.	3.3	405
4	Regulation of cholesterol and sphingomyelin metabolism by amyloid-Î² and presenilin. Nature Cell Biology, 2005, 7, 1118-1123.	4.6	404
5	Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Annals of Neurology, 2002, 52, 346-350.	2.8	372
6	TLR2 Is a Primary Receptor for Alzheimerâ€™s Amyloid Î² Peptide To Trigger Neuroinflammatory Activation. Journal of Immunology, 2012, 188, 1098-1107.	0.4	346
7	Worldâ€Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimer's and Dementia, 2020, 16, 1078-1094.	0.4	257
8	Inhibition of Intracellular Cholesterol Transport Alters Presenilin Localization and Amyloid Precursor Protein Processing in Neuronal Cells. Journal of Neuroscience, 2002, 22, 1679-1689.	1.7	232
9	Altered Gut Microbiome Composition and Tryptic Activity of the 5xFAD Alzheimerâ€™s Mouse Model. Journal of Alzheimer's Disease, 2017, 56, 775-788.	1.2	230
10	Cerebrospinal fluid A?42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Annals of Neurology, 1999, 45, 504-511.	2.8	224
11	Docosahexaenoic Acid Reduces Amyloid Î² Production via Multiple Pleiotropic Mechanisms. Journal of Biological Chemistry, 2011, 286, 14028-14039.	1.6	201
12	Alzheimerâ€™s disease: the lipid connection. Journal of Neurochemistry, 2007, 103, 159-170.	2.1	178
13	24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurology, The, 2017, 16, 965-975.	4.9	175
14	Non-AÎ² Component of Alzheimer's Disease Amyloid (NAC) Revisited. American Journal of Pathology, 1999, 155, 1173-1181.	1.9	173
15	Key Factors in Alzheimer's Disease: Î²â€amyloid Precursor Protein Processing, Metabolism and Intraneuronal Transport. Brain Pathology, 2001, 11, 1-11.	2.1	159
16	Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neuroscience Letters, 2002, 324, 83-85.	1.0	153
17	Neprilysin and AÎ² Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2013, 5, 98.	1.7	129
18	Plant Sterols the Better Cholesterol in Alzheimer's Disease? A Mechanistical Study. Journal of Neuroscience, 2013, 33, 16072-16087.	1.7	111

#	Article	IF	Citations
19	Independent Inhibition of Alzheimer Disease Î²- and Î³-Secretase Cleavage by Lowered Cholesterol Levels. Journal of Biological Chemistry, 2008, 283, 11302-11311.	1.6	110
20	From brain to food: Analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholinâ€“plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry. Journal of Chromatography A, 2011, 1218, 7713-7722.	1.8	100
21	Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42. Neurobiology of Aging, 2005, 26, 785-788.	1.5	99
22	Cholesterol impairs autophagy-mediated clearance of amyloid beta while promoting its secretion. Autophagy, 2018, 14, 1129-1154.	4.3	97
23	Dietary intake of plant sterols stably increases plant sterol levels in the murine brain. Journal of Lipid Research, 2012, 53, 726-735.	2.0	95
24	Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human Î±-synuclein. Neurobiology of Disease, 2005, 20, 303-313.	2.1	93
25	Plasmalogen synthesis is regulated via alkylâ€dihydroxyacetonephosphateâ€synthase by amyloid precursor protein processing and is affected in Alzheimerâ€™s disease. Journal of Neurochemistry, 2011, 116, 916-925.	2.1	93
26	Î±-Synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease Î²-amyloid plaque cores. Neuroscience Letters, 1999, 266, 213-216.	1.0	88
27	Cholesterol, AÎ² and Alzheimer's disease. Trends in Neurosciences, 2001, 24, S45-S48.	4.2	88
28	Ibuprofen Decreases Cytokine-Induced Amyloid Beta Production in Neuronal Cells. Neurobiology of Disease, 2001, 8, 1094-1101.	2.1	86
29	Unfolded protein response signaling by transcription factor XBPâ€1 regulates ADAM10 and is affected in Alzheimer's disease. FASEB Journal, 2014, 28, 978-997.	0.2	86
30	Increased expression of the Î³â€secretase components presenilinâ€1 and nicastrin in activated astrocytes and microglia following traumatic brain injury. Glia, 2008, 56, 552-567.	2.5	84
31	Alzheimer's disease pathology is attenuated in a <scp>CD</scp>38â€deficient mouse model. Annals of Neurology, 2015, 78, 88-103.	2.8	81
32	Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. Neurobiology of Disease, 2006, 23, 573-577.	2.1	80
33	36â€month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 29-40.	0.4	77
34	APP Function and Lipids: A Bidirectional Link. Frontiers in Molecular Neuroscience, 2017, 10, 63.	1.4	76
35	The Impact of Vitamin E and Other Fat-Soluble Vitamins on AlzheimerÂ´s Disease. International Journal of Molecular Sciences, 2016, 17, 1785.	1.8	75
36	Amyloid beta as a regulator of lipid homeostasis. Trends in Molecular Medicine, 2007, 13, 337-344.	3.5	72

#	Article	IF	Citations
37	Trans fatty acids enhance amyloidogenic processing of the Alzheimer amyloid precursor protein (APP). Journal of Nutritional Biochemistry, 2012, 23, 1214-1223.	1.9	69
38	Reduced cerebrospinal fluid estradiol levels are associated with increased Î²-amyloid levels in female patients with Alzheimer's disease. Neuroscience Letters, 2001, 307, 122-124.	1.0	68
39	Vitamin D and Its Analogues Decrease Amyloid-Î² (AÎ²) Formation and Increase AÎ²-Degradation. International Journal of Molecular Sciences, 2017, 18, 2764.	1.8	68
40	Quantification of Alzheimer Amyloid Î² Peptides Ending at Residues 40 and 42 by Novel ELISA Systems. Molecular Medicine, 2000, 6, 291-302.	1.9	66
41	Role of amyloid beta in lipid homeostasis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 966-974.	1.2	65
42	Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention. Journal of Lipid Research, 2017, 58, 2083-2101.	2.0	65
43	The Impact of Cholesterol, DHA, and Sphingolipids on Alzheimerâ€™s Disease. BioMed Research International, 2013, 2013, 1-16.	0.9	64
44	Amyloid Precursor Protein (APP) Mediated Regulation of Ganglioside Homeostasis Linking Alzheimer's Disease Pathology with Ganglioside Metabolism. PLoS ONE, 2012, 7, e34095.	1.1	61
45	Plasmalogens Inhibit APP Processing by Directly AffectingÎ³-Secretase Activity in Alzheimerâ€™s Disease. Scientific World Journal, The, 2012, 2012, 1-15.	0.8	61
46	Neural expression profile of Î±-synuclein in developing human cortex. NeuroReport, 1999, 10, 2799-2803.	0.6	60
47	The Isoform-Specific Pathological Effects of ApoE4 in vivo are Prevented by a Fish Oil (DHA) Diet and are Modified by Cholesterol. Journal of Alzheimer's Disease, 2012, 28, 667-683.	1.2	59
48	The role of APP proteolytic processing in lipid metabolism. Experimental Brain Research, 2012, 217, 365-375.	0.7	59
49	Tenascin-C deficiency ameliorates Alzheimer's disease-related pathology in mice. Neurobiology of Aging, 2013, 34, 2389-2398.	1.5	58
50	Nutrition and the ageing brain: Moving towards clinical applications. Ageing Research Reviews, 2020, 62, 101079.	5.0	56
51	APP intracellular domain derived from amyloidogenic ÃŽÂ²- and ÃŽÂ³-secretase cleavage regulates neprilysin expression. Frontiers in Aging Neuroscience, 2015, 7, 77.	1.7	53
52	Apolipoprotein E-∈A allele and Alzheimer's disease. Lancet, The, 1993, 342, 1308-1309.	6.3	51
53	Deficiency of Sphingosine-1-phosphate Lyase Impairs Lysosomal Metabolism of the Amyloid Precursor Protein. Journal of Biological Chemistry, 2014, 289, 16761-16772.	1.6	50
54	Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimerâ€™s disease-related symptoms and pathology. Brain, 2011, 134, 278-292.	3.7	49

#	Article	IF	Citations
55	Impact of Vitamin D on Amyloid Precursor Protein Processing and Amyloid-Î² Peptide Degradation in Alzheimer's Disease. Neurodegenerative Diseases, 2014, 13, 75-81.	0.8	49
56	Special lipid-based diets alleviate cognitive deficits in the APPswe/PS1dE9 transgenic mouse model of Alzheimer's disease independent of brain amyloid deposition. Journal of Nutritional Biochemistry, 2014, 25, 157-169.	1.9	49
57	Eicosapentaenoic acid and docosahexaenoic acid increase the degradation of amyloid-Î² by affecting insulin-degrading enzyme. Biochemistry and Cell Biology, 2016, 94, 534-542.	0.9	47
58	Oxidized Docosahexaenoic Acid Species and Lipid Peroxidation Products Increase Amyloidogenic Amyloid Precursor Protein Processing. Neurodegenerative Diseases, 2016, 16, 44-54.	0.8	47
59	Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. Psychiatry Research, 2003, 120, 231-238.	1.7	46
60	World Wide Fingers will advance dementia prevention. Lancet Neurology, The, 2018, 17, 27.	4.9	46
61	The Transmembrane Domain of the Amyloid Precursor Protein in Microsomal Membranes Is on Both Sides Shorter than Predicted. Journal of Biological Chemistry, 2003, 278, 6803-6808.	1.6	45
62	Upregulation of <scp>PGC</scp>â€1Î± expression by <scp>A</scp>lzheimer's diseaseâ€associated pathway: presenilin 1/amyloid precursor protein (<scp>APP</scp>)/intracellular domain of <scp>APP</scp>. Aging Cell, 2014, 13, 263-272.	3.0	45
63	Intracellular APP Domain Regulates Serine-Palmitoyl-CoA Transferase Expression and Is Affected in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-8.	1.1	43
64	Shedding of APP limits its synaptogenic activity and cell adhesion properties. Frontiers in Cellular Neuroscience, 2014, 8, 410.	1.8	43
65	The Role of NAC in Amyloidogenesis in Alzheimer's Disease. American Journal of Pathology, 2000, 156, 734-735.	1.9	40
66	Amyloid beta-protein and lipid metabolism. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 1991-2001.	1.4	38
67	Î³-Secretase Cleavage Site Specificity Differs for Intracellular and Secretory Amyloid Î². Journal of Biological Chemistry, 2003, 278, 13077-13085.	1.6	35
68	Tocotrienol Affects Oxidative Stress, Cholesterol Homeostasis and the Amyloidogenic Pathway in Neuroblastoma Cells: Consequences for Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2016, 17, 1809.	1.8	35
69	Regulation of hippocampal cholesterol metabolism by apoE and environmental stimulation. Journal of Neurochemistry, 2005, 95, 987-997.	2.1	34
70	Effect of Different Phospholipids on Î±-Secretase Activity in the Non-Amyloidogenic Pathway of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2013, 14, 5879-5898.	1.8	34
71	Alzheimer's Disease Î²A4 Protein Release and Amyloid Precursor Protein Sorting Are Regulated by Alternative Splicing. Journal of Biological Chemistry, 1996, 271, 13208-13214.	1.6	32
72	A Nutritional Approach to Ameliorate Altered Phospholipid Metabolism in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 41, 715-717.	1.2	30

#	Article	IF	Citations
73	Vitamin E: Curse or benefit in Alzheimer's disease? A systematic investigation of the impact of Î±-, Î³- and Î´-tocopherol on AÎ² generation and degradation in neuroblastoma cells. Journal of Nutrition, Health and Aging, 2015, 19, 646-654.	1.5	29
74	PS Dependent APP Cleavage Regulates Glucosylceramide Synthase and is Affected in Alzheimer's Disease. Cellular Physiology and Biochemistry, 2014, 34, 92-110.	1.1	28
75	Therapeutic Perspectives in Alzheimers Disease. Recent Patents on CNS Drug Discovery, 2006, 1, 119-127.	0.9	25
76	Methylxanthines and Neurodegenerative Diseases: An Update. Nutrients, 2021, 13, 803.	1.7	24
77	Role of Amyloid Precursor Protein, Amyloid-Î² and Î³-Secretase in Cholesterol Maintenance. Neurodegenerative Diseases, 2006, 3, 305-311.	0.8	20
78	Effect of Caffeine and Other Methylxanthines on AÎ²-Homeostasis in SH-SY5Y Cells. Biomolecules, 2019, 9, 689.	1.8	20
79	Rescue of Hypovitaminosis A Induces Non-Amyloidogenic Amyloid Precursor Protein (APP) Processing. Current Alzheimer Research, 2016, 13, 1277-1289.	0.7	20
80	Sphingomyelin Synthase 1 Is Essential for Male Fertility in Mice. PLoS ONE, 2016, 11, e0164298.	1.1	19
81	Potential external source of AÎ² in biological samples. Nature Cell Biology, 2002, 4, E164-E165.	4.6	17
82	Profiling of Alzheimerâ€™s disease related genes in mild to moderate vitamin D hypovitaminosis. Journal of Nutritional Biochemistry, 2019, 67, 123-137.	1.9	17
83	New Alzheimer Amyloid Î² Responsive Genes Identified in Human Neuroblastoma Cells by Hierarchical Clustering. PLoS ONE, 2009, 4, e6779.	1.1	15
84	Medium-Chain Length Fatty Acids Enhance AÎ² Degradation by Affecting Insulin-Degrading Enzyme. Cells, 2021, 10, 2941.	1.8	14
85	Subcellular localization of the Alzheimer's disease amyloid precursor protein and derived polypeptides expressed in a recombinant yeast system. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1998, 5, 79-89.	1.4	13
86	Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical AÎ²42reduces their differentiation potential. BMC Medicine, 2008, 6, 38.	2.3	13
87	Response of Toll-like receptors in experimental Guillainâ€“BarrÃ© syndrome: A kinetic analysis. Neuroscience Letters, 2012, 518, 154-160.	1.0	13
88	Unique Role of Caffeine Compared to Other Methylxanthines (Theobromine, Theophylline,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 Td Type Cells. International Journal of Molecular Sciences, 2020, 21, 9015.	1.8	13
89	Shotgun lipidomics of liver and brain tissue of Alzheimerâ€™s disease model mice treated with acitretin. Scientific Reports, 2021, 11, 15301.	1.6	12
90	GM1 up-regulates Ubiquilin 1 expression in human neuroblastoma cells and rat cortical neurons. Neuroscience Letters, 2006, 407, 59-63.	1.0	9

#	Article	IF	Citations
91	Clinical characterization of a presenilin 1 mutation (F177S) in a family with very early-onset Alzheimer's disease in the third decade of life. , 2014, 10, e27-e39.		9
92	Paradoxical effects of mutant ubiquitin on AÎ² plaque formation in an Alzheimer mouse model. Neurobiology of Aging, 2018, 72, 62-71.	1.5	9
93	Targeted Lipidomics of Mitochondria in a Cellular Alzheimerâ€™s Disease Model. Biomedicines, 2021, 9, 1062.	1.4	9
94	Increased Expression of Presenilin 2 Inhibits Protein Synthesis. Molecular and Cellular Neurosciences, 2002, 19, 111-124.	1.0	8
95	Transcriptional repression of the ectodomain sheddase ADAM10 by TBX2 and potential implication for Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2019, 76, 1005-1025.	2.4	8
96	Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid AÎ² 40 and tau in patients with intractable unipolar depression. International Journal of Geriatric Psychiatry, 2011, 26, 1283-1291.	1.3	7
97	Regulatory feedback cycle of the insulinâ€degrading enzyme and the amyloid precursor protein intracellular domain: Implications for Alzheimerâ€™s disease. Aging Cell, 2020, 19, e13264.	3.0	7
98	The impact of capsaicinoids on APP processing in Alzheimerâ€™s disease in SH-SY5Y cells. Scientific Reports, 2020, 10, 9164.	1.6	7
99	Research diagnostic criteria for Alzheimerâ€™s disease: findings from the LipiDiDiet randomized controlled trial. Alzheimer's Research and Therapy, 2021, 13, 64.	3.0	6
100	Modeling the underlying biological processes in Alzheimer's disease using a multivariate competing risk joint model. Statistics in Medicine, 2022, 41, 3421-3433.	0.8	6
101	Using joint models to disentangle intervention effect types and baseline confounding: an application within an intervention study in prodromal Alzheimerâ€™s disease with Fortasyn Connect. BMC Medical Research Methodology, 2019, 19, 163.	1.4	5
102	Elevated Testosterone Level and Urine Scent Marking in Male 5xFAD Alzheimer Model Mice. Current Alzheimer Research, 2020, 17, 80-92.	0.7	5
103	Going the wrong road: Fyn and targeting of amyloid precursor protein to lipid rafts. Journal of Neurochemistry, 2011, 118, 677-679.	2.1	4
104	Recent Understanding of the Molecular Mechanisms of Alzheimer?s Disease. Journal of Addiction Research & Therapy, 0, s5, .	0.2	4
105	Transnasal delivery of human A-beta peptides elicits impaired learning and memory performance in wild type mice. BMC Neuroscience, 2016, 17, 44.	0.8	3
106	A competing risk joint model for dealing with different types of missing data in an intervention trial in prodromal Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2021, 13, 63.	3.0	3
107	Methylxanthines Induce a Change in the AD/Neurodegeneration-Linked Lipid Profile in Neuroblastoma Cells. International Journal of Molecular Sciences, 2022, 23, 2295.	1.8	3
108	The Effects of Glycerophospholipids and Fatty Acids on APP Processing. , 2016, , 377-421.		2

#	Article	IF	Citations
109	DTâ€01â€04: Effects of Fortasyn Connect (Souvenaid) on Longitudinal Brain Atrophy Measures in Prodromal Alzheimerâ€™s Disease: Results of the Doubleâ€Blind Randomised Controlled Lipididiet Trial. Alzheimer's and Dementia, 2016, 12, P1135.	0.4	2
110	The Effects of Vitamin D Deficiency on Neurodegenerative Diseases. , 2020, , .		2
111	Alzheimer-Demenz. , 2011, , 47-72.		2
112	Impact of Vitamin D3 Deficiency on Phosphatidylcholine-/Ethanolamine, Plasmalogen-, Lyso-Phosphatidylcholine-/Ethanolamine, Carnitine- and Triacyl Glyceride-Homeostasis in Neuroblastoma Cells and Murine Brain. Biomolecules, 2021, 11, 1699.	1.8	2
113	PEX19 Coordinates Neutral Lipid Storage in Cells in a Peroxisome-Independent Fashion. Frontiers in Cell and Developmental Biology, 2022, 10, 859052.	1.8	2
114	Alzheimerâ€™s disease prevention â€“ The emerging role of lipids and diet. Oleagineux Corps Gras Lipides, 2007, 14, 182-185.	0.2	1
115	Intracellular and Secreted AÎ²42/40 Ratios Are Differently Influenced by APP Mutations. , 0, , 479-486.		0
116	P4-351: A PLASMA PHOSPHOLIPID BIOMARKER PROFILE FOR DETECTING PRECLINICAL ALZHEIMER'S DISEASE CAN BE MODIFIED BY ORAL INTAKE OF NUTRIENTS THAT INCREASE PHOSPHOLIPID SYNTHESIS. , 2014, 10, P916-P917.		0
117	Linking Alzheimerâ€™s Disease, B-Amyloid, and Lipids. , 2004, , .		0
118	Cholesterol and AÎ² Production: Methods for Analysis of Altered Cholesterol De Novo Synthesis. , 2008, , 221-230.		0